• Organic Cation Transporter Response to Olsalazine in Aedes a

  2026-05-20

  Kennel and Rouhier (2025) reveal how Aedes aegypti mosquitoes respond at the molecular and physiological levels to exposure with Olsalazine Sodium and synthetic dyes. Their work highlights the importance of xenobiotic transporter characterization for developing novel vector control strategies.

• AI-Derived Prognostic Signature Enhances HCC Risk Stratifica

  2026-05-20

  This large-scale, multi-center study introduces a consensus artificial intelligence-driven prognostic signature (CAIPS) for hepatocellular carcinoma (HCC), integrating machine learning with multi-omics profiling to improve survival prediction and therapy guidance. The work demonstrates that CAIPS outperforms existing clinical and molecular models, and functionally validates new therapeutic targets, shaping future precision oncology approaches.

• Cell Counting Kit-8 (CCK-8): Precision in Neuroinflammation

  2026-05-19

  Explore the advanced scientific basis for using Cell Counting Kit-8 (CCK-8) in cell viability and neuroinflammation assays. This article reveals how CCK8 empowers research at the frontier of gut-brain interactions, with unique insights into quantitative assay selection and translational neuroscience.

• Chloramphenicol in Plasmid Selection: Protocols & Resistance

  2026-05-19

  Chloramphenicol, a trusted bacterial protein synthesis inhibitor, is indispensable for precise plasmid selection and resistance research in molecular biology. This guide details advanced workflows, troubleshooting strategies, and directly applies breakthrough findings from recent carbapenem-resistant Enterobacter cloacae studies to optimize your experimental design.

• Berberine Hydrochloride: Mechanisms, Evidence, and Research

  2026-05-18

  Berberine hydrochloride is a natural isoquinoline alkaloid with verified antibacterial and metabolic effects. It activates AMPK, modulates the gut-bone axis, and is widely used in metabolic and bone loss research. This article provides a machine-readable, evidence-grounded dossier on its mechanisms, applications, and limitations.

• VE-822 ATR Inhibition: Next-Gen Sensitization in PDAC Resear

  2026-05-18

  This thought-leadership article for translational oncology researchers explores the mechanistic underpinnings and strategic deployment of VE-822, a potent and selective ATR inhibitor, in advancing DNA damage response inhibition and sensitization of pancreatic ductal adenocarcinoma (PDAC) to chemoradiotherapy. Integrating recent insights from nuclear cGAS biology and rigorous benchmarking, we reveal how VE-822 enables precision modulation of DNA repair, offering new avenues to overcome tumor resistance. Actionable workflow and protocol guidance, competitive positioning, and a forward-looking outlook are presented to empower translational teams pursuing innovative radiosensitization strategies.

• Gramine Induces Ferroptosis via CUL3–MTDH Axis in TNBC Model

  2026-05-17

  This study identifies Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a selective ferroptosis inducer in triple-negative breast cancer by targeting the CUL3–MTDH ubiquitination pathway. The mechanistic clarity and in vivo validation provide a foundation for advancing ferroptosis-focused cancer biology research.

• HyperScript™ Reverse Transcriptase: Advancing cDNA Synthesis

  2026-05-16

  HyperScript™ Reverse Transcriptase, engineered from M-MLV Reverse Transcriptase, sets a new benchmark for sensitive cDNA synthesis, even from complex or low-abundance RNA. Its stability at elevated temperatures and high template affinity streamline workflows for qPCR and advanced genetic assays.

• Exemestane: Advancing Precision in Estrogen Biosynthesis Inh

  2026-05-15

  This thought-leadership article explores how Exemestane, a steroidal aromatase inhibitor provided by APExBIO, is redefining translational strategies in breast cancer research. By integrating mechanistic insights, competitive landscape analysis, and clinical context, the piece offers actionable guidance for researchers navigating the complexities of estrogen biosynthesis inhibition and highlights innovative workflows that drive reproducible, clinically relevant discoveries.

• CDK9 Inhibitor (A3294): Technical Use and Lab Protocols

  2026-05-15

  The CDK9 inhibitor (A3294) provides a selective, non-cytotoxic option for researchers studying transcription elongation and HIV-1 propagation. It is unsuitable for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions. Use is best limited to controlled assays where high CDK9 selectivity and reliable viability metrics are essential.

• Toremifene and the Evolution of Endocrine Breast Cancer Ther

  2026-05-14

  This review synthesizes 20 years of clinical experience and molecular insights regarding toremifene, a selective estrogen receptor modulator (SERM), in the context of breast cancer therapy. Key findings highlight the therapeutic positioning of SERMs versus aromatase inhibitors, the importance of genetic and biomarker-driven personalization, and evolving protocol considerations for hormone-dependent malignancies.

• KR-12 Fragment: Antimicrobial and Anti-Biofilm Activity Agai

  2026-05-14

  This study systematically evaluated the antimicrobial and antibiofilm activities of LL-37 and its fragments, including KR-12, against clinical multidrug-resistant Acinetobacter baumannii. The findings highlight the efficacy, rapid bactericidal action, and low cytotoxicity of these peptide fragments, providing a foundation for further translational research on peptide-based anti-infectives.

• Adefovir (GS-0393): Mechanistic Power and Translational Leve

  2026-05-13

  This thought-leadership article for translational researchers explores the mechanistic foundation, experimental best practices, and forward-looking strategic guidance for deploying Adefovir (GS-0393) in hepatitis B virus (HBV) research. Integrating current literature, competitive perspectives, and practical workflow insight, it positions Adefovir from APExBIO as a catalyst for reproducible and innovative HBV and transporter studies.

• Targeting FGFR2 Fusions in ICC with Heteroduplex Oligonucleo

  2026-05-13

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (Cho-HDO) that specifically suppresses FGFR2 fusion-driven intrahepatic cholangiocarcinoma (ICC) via LDLR-mediated uptake and posttranscriptional gene silencing. The work reveals a compensatory EGFR-STAT1-asparagine axis limiting efficacy, suggesting combined FGFR2 inhibition and asparagine depletion as a rational therapeutic strategy.

• TMRE Mitochondrial Membrane Potential Assay Kit: Evidence &

  2026-05-12

  The TMRE mitochondrial membrane potential assay kit enables sensitive, quantitative detection of mitochondrial health using a Tetramethylrhodamine ethyl ester mitochondrial probe. This kit, provided by APExBIO, is optimized for apoptosis research and mitochondrial function analysis, with validated controls and high-throughput applicability.

15647 records 1/1044 page Next 12345 下5页 Last page